Clinical Applications of High-Frequency Oscillations
Public ClinicalTrials.gov record NCT00600717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Localizing Functional Brain Cortices and Epileptogenic Zones With High Frequency Brain Signals
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to utilize high-frequency brain signals (HFBS) to localize functional brain areas and characterize HFBS in epilepsy, migraine, and other brain disorders. Our goal is to create the world's first high-frequency MEG/EEG/ECoG/SEEG database for the developing brain. HFBS include high-gamma activation/oscillations, high-frequency oscillations (HFOs), ripples, fast ripples, spikelets, fast spikelets, and very high-frequency oscillations (VHFOs). While terminologies and frequency bands may vary among reports, both HFOs and high-gamma waves are crucial for understanding brain function and developing potential treatments for neurological disorders. We have been developing an intelligent software platform to analyze signals from low to very high-frequency ranges across multiple frequency bands. To achieve these goals, we have developed several innovative techniques and software packages: * Accumulated spectrogram * Accumulated source imaging * Frequency-encoded source imaging * Multi-frequency analysis at source levels * Artificial intelligence detection of HFOs * Neural network analysis (Graph Theory) * Other techniques (e.g., Independent Component Analysis, virtual sensors) These methods enable researchers to better understand the characteristics and significance of HFOs and high-gamma brain waves, contributing to advancements in the diagnosis and treatment of neurological disorders.
Study identification
- NCT ID
- NCT00600717
- Recruitment status
- Withdrawn
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 1 Day to 69 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2000
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2027
- Last update posted
- Feb 3, 2026
2000 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MEG | Cincinnati | Ohio | 45229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00600717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00600717 live on ClinicalTrials.gov.